Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma

Seung Min Hahn, Hyo Sun Kim, Dong Joon Kim, Sungchul Lee, Chuhl Joo Lyu, Jung Woo Han

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or group E (n = 5, 38.5%). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.

Original languageEnglish
Pages (from-to)74-82
Number of pages9
JournalPediatric Hematology and Oncology
Volume33
Issue number1
DOIs
Publication statusPublished - 2016 Jan 2

Fingerprint

Retinoblastoma
Drug Therapy
Neoplasm Micrometastasis
Therapeutics
Central Nervous System
Survival

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Hahn, Seung Min ; Kim, Hyo Sun ; Kim, Dong Joon ; Lee, Sungchul ; Lyu, Chuhl Joo ; Han, Jung Woo. / Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma. In: Pediatric Hematology and Oncology. 2016 ; Vol. 33, No. 1. pp. 74-82.
@article{569ad8513bd34029bc0221922c706790,
title = "Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma",
abstract = "The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7{\%}), group C (n = 2, 15.4{\%}), group D (n = 5, 38.5{\%}), or group E (n = 5, 38.5{\%}). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7{\%}. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.",
author = "Hahn, {Seung Min} and Kim, {Hyo Sun} and Kim, {Dong Joon} and Sungchul Lee and Lyu, {Chuhl Joo} and Han, {Jung Woo}",
year = "2016",
month = "1",
day = "2",
doi = "10.3109/08880018.2015.1135363",
language = "English",
volume = "33",
pages = "74--82",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "1",

}

Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma. / Hahn, Seung Min; Kim, Hyo Sun; Kim, Dong Joon; Lee, Sungchul; Lyu, Chuhl Joo; Han, Jung Woo.

In: Pediatric Hematology and Oncology, Vol. 33, No. 1, 02.01.2016, p. 74-82.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma

AU - Hahn, Seung Min

AU - Kim, Hyo Sun

AU - Kim, Dong Joon

AU - Lee, Sungchul

AU - Lyu, Chuhl Joo

AU - Han, Jung Woo

PY - 2016/1/2

Y1 - 2016/1/2

N2 - The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or group E (n = 5, 38.5%). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.

AB - The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or group E (n = 5, 38.5%). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.

UR - http://www.scopus.com/inward/record.url?scp=84959043055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959043055&partnerID=8YFLogxK

U2 - 10.3109/08880018.2015.1135363

DO - 10.3109/08880018.2015.1135363

M3 - Article

C2 - 26901285

AN - SCOPUS:84959043055

VL - 33

SP - 74

EP - 82

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 1

ER -